Last month, Moderna Health announced advancements in Covid-19 vaccine trials, prompting speculation that a vaccine might be available as early as next year. But with this increased optimism comes challenges in manufacturing and distribution. Vaccines take time to produce, and the initial supply might not meet US demands. As the race for a Covid-19 vaccine heats up, policymakers must confront a series of pressing questions: Who should get the vaccine first, and how should that decision be made?
Last month, Moderna Health announced advancements in Covid-19 vaccine trials, prompting speculation that a vaccine might be available as early as next year. But with this increased optimism comes challenges in manufacturing and distribution. Vaccines take time to produce, and the initial supply might not meet US demands. As the race for a Covid-19 vaccine heats up, policymakers must confront a series of pressing questions: Who should get the vaccine first, and how should that decision be made?
